What innovative solutions are being developed to combat antibiotic resistance?

Antibiotic resistance is prompting researchers to look beyond simply making more versions of existing drugs. The most promising work spans new medicines, faster diagnosis and treatments that help the body fight infection in other ways. Many approaches are still being tested, so their potential should not be mistaken for proven, widely available care.

New ways to treat resistant infections

• Bacteriophages: These viruses infect bacteria, and can sometimes be selected or engineered to target a resistant strain. Engineered bacteriophages for resistant infections are an active area of research, though matching the right phage to a patient and delivering it effectively can be challenging.
• Antibiotic helpers: Some experimental drugs are designed to block bacterial defenses, such as enzymes that destroy antibiotics. Antibiotic resistance enzyme inhibitors could make certain existing antibiotics useful again when paired with them.
• New drug targets: Researchers are investigating antibiotics that attack bacteria in different ways, as well as anti-virulence treatments that interfere with a pathogen’s ability to cause disease without necessarily killing it outright.
• Microbiome-based treatments: Carefully selected microbes or microbiome products may help restore protective gut bacteria after disruption, particularly in recurrent infections. These treatments are being studied for specific conditions and are not a general replacement for antibiotics.
• CRISPR-based approaches: In theory, gene-targeting tools could disable resistance genes or selectively kill harmful bacteria. Getting the tools safely and reliably to the right bacteria remains a major hurdle.

Getting the right treatment sooner

Resistance also grows when antibiotics are used unnecessarily or when an infection’s cause is unclear. Rapid point-of-care diagnostics aim to identify a pathogen, and sometimes its likely drug susceptibility, faster than conventional lab testing. Better results could help clinicians choose an effective medicine sooner and avoid antibiotics that are unlikely to help.

Vaccines can prevent some infections before antibiotics are needed, while careful prescribing and infection-control practices reduce opportunities for resistant bacteria to spread. No single innovation will solve the problem: progress is likely to depend on combining better prevention, diagnostics and treatments, and ensuring new options can be tested and made available responsibly.